Posts Tagged ‘BDSI’
RTP Wrapup 10/23
Thursday, October 22, 2009, 5:43 pm No Comments | Post a CommentWorries of Tysabri’s side effect risks are on the rise, BDSI goes on a publicity blitz to boost its stock and Trimeris finds a potential buyer.
RTP Wrapup 9/4
Thursday, September 3, 2009, 6:23 pm No Comments | Post a CommentA report offers hope that federal funds could become available for economic development in innovation hot spots such as the Research Triangle area, Bayer CropScience adds a research collaboration to recent efforts of creating better biotech seeds and Family Health International, a Durham organization that aims to improve public health worldwide, uses realty shows to stem the spread of HIV/AIDS.
BDSI stock drops on Onsolis approval
Friday, July 17, 2009, 12:19 pm No Comments | Post a CommentGetting its first product, a painkiller, approved for sale was a triumph for BioDelivery Sciences.
Champagne corks popped at BDSI Thursday, the day the Food and Drug Administration let the small Raleigh drug development company know that Onsolis, a potent pain patch for cancer patients, had passed all regulatory hurdles. On Friday, analysts congratulated BDSI CEO Mark Sirgo during a conference call. By Monday, BDSI expected to have about $27 million more in the bank, a payment its Swedish partner Meda promised upon regulatory approval of Onsolis.
“It’s been a long haul,” Sirgo told analysts in the call Friday. “This is a fantastic day for our company.”
So why did BDSI’s stock drop 5 percent on a day when it should have risen?
